Introduction 38
The purpose of this paper is to review the capabilities of various heating technologies available 39 for treatment of bladder cancer, with an eye toward correlating typical performance 40 characteristics of each approach with the clinical requirements. Bladder tumors present either 41 as non-muscle invasive (NMIBC), 70%, or as muscle invasive (MIBC), 30%, carcinomas. ( 
1) 42
While most clinical studies to date have concerned treatment of NMIBC superficial disease 43 limited to the interior wall of bladder,(2-7) future clinical trials must address the more aggressive 44 MIBC that extends beyond the bladder wall out into surrounding pelvic tissues. Thus depending 45 on the extent of disease, heating systems are required to accomplish different clinical goals of 46 treatment. 47 3 chemotherapy. For MIBC, i.e. tumor stages T2-T4a, the hyperthermia target extends to much 56 greater depths and a heating system for MIBC must be able to deposit significant power 57 throughout the bladder wall and for some patients out into extravesical pelvic tissues to enhance 58 the delivery and activation of systemically administered chemotherapeutic throughout the 59 muscle invasive component of disease. 
66
The different tumor pathology of NMIBC and MIBC must be reflected in the clinical practice of 67 applying adjuvant hyperthermia and thus the requirements on technology for heating these two 68 diseases are quite different. For NMIBC with Tis, Ta, and T1 tumors, the target to be heated is 69 well defined (~1 mm deep) and the technological demands for adequate heating of such shallow 70 depth tumors are relatively easily met with uncomplicated thermal conduction heating solutions. 71
For MIBC however, the tumor is ill-defined and variable in depth, size, shape and location 72 (especially the advanced cases) demanding much higher flexibility in power deposition 73 capabilities of the hyperthermia system to adequately heat the desired target volume. 
Typical EM deep heating systems 157
The BSD2000 RF Phased Array Hyperthermia System (Pyrexar Corp., Salt Lake City UT, USA) 158 
Principles: 291
The most straightforward approach to heating tissue is to apply a heated surface in intimate 292 contact with the target tissue to enable heat transfer across a thermal gradient. To uniformly 293 heat the interior wall of a complex shaped bladder cavity, this simple heat transfer approach is 294 best accomplished by vigorously circulating externally heated fluid (and drug) at a controlled 295 temperature throughout the bladder. Due to the dynamics of turbulent flow, there is a non-296 uniform velocity profile across the inner bladder surface but with sufficient circulation the entire 297 target tissue on the inner wall of bladder will come in contact with rapidly moving near equi-298 temperature fluid. With no power deposition directly in tissue, the resulting temperature 299 distribution is dependent only on bladder tissue thermal parameters rather than heterogeneous 300 electrical or acoustic tissue properties. Using thermal conduction only heating, maximum tissue 301 temperature is readily determined with confidence to be the measured input temperature of the 302 circulating fluid, and thus thermal toxicity is easily avoided. The constant temperature interface 303 should provide relatively uniform heating of the inner surface of bladder even with 304 heterogeneous thermal properties that effect heat penetration into the wall. While temperature 305 of the bladder lumen may be nearly constant, there is a steep temperature gradient within the 306 bladder wall as heat dissipates rapidly into surrounding cooler tissues. Especially because of 307 heat losses to normothermic blood perfusing the bladder wall tissues, the penetration depth of 308 effective heating is limited when the driving thermal gradient is only 7C (44 -37C). The 309 accompanying modeling and thermal dosimetry paper in this special issue specifically 310 addresses penetration of heat into the bladder wall with various heating technologies. Previous 311 studies of temperature gradients in perfused tissue adjacent to a hot (or cold) surface show that 312 the effective heating potential of a 7C thermal gradient extend no more than 2-3 mm deep.(56, 313 57). For NMIBC cancers that extend <2mm into the bladder wall, this thermal gradient induced 314 heating should be sufficient for effective treatment. Clinical experience at three institutes using 315 two different intravesical thermal conduction heating systems indicates excellent performance 316 with a very high percentage of patients completing the prescribed treatment course (see Table  317 1). 318 319 Alternatively, thermal conduction heating from inside the bladder may be accomplished without 320 the need to circulate expensive chemotherapeutic through multi-lumen connecting tubes to an 321 external temperature regulating heat exchanger. Efforts are underway to investigate the use of 322 ferromagnetic nanoparticle (MNP) solutions that can be mixed with drug and injected into the 323 bladder through a standard Foley catheter. With this approach, the MNP are heated via 324 magnetic induction coupling from an externally applied alternating magnetic field, usually at a 325 frequency of 50-100 kHz to minimize direct eddy current heating in the pelvis. As demonstrated 326 in preclinical studies, the MNP can produce sufficient heating to raise the temperature of the 327 chemotherapeutic mixture in bladder to the desired treatment temperature.(58) Inductively 328 coupled heating is distributed throughout the MNP solution producing relatively homogeneous 329 internal bladder temperature, and convection current mixing of bladder contents further 330 minimizes temperature gradients during treatment. For magnetic coupled nanoparticle solutions, 331 temperature must be monitored with a probe inserted into the bladder through the Foley 332 catheter. Unlike the rapidly circulated heated fluid approach, the maximum bladder temperature 333 is not known precisely as the intraluminal probe will generally underestimate the peak 334 temperature due to small gradients within the unstirred magnetic fluid/chemotherapeutic 335
mixture. 336 337

Typical intravesical thermal conduction systems: 338
There are two commercial systems that heat bladder by circulating heated drug through the 339 
Devices and Techniques for Pre-Clinical Bladder Heating 357
Preclinical studies are often used in the development and optimization of new cancer treatment 358 strategies. Rodent studies are most common though larger animals are also used to model the 359 human treatment situation more closely. Since human bladder capacity is approximately 500 360 ml,(62) the small size of bladder in mice (~ 0.15 ml) and rats (~ 1 -1.5 ml) requires different 361 heating systems(58, 63). Farm pigs are also used for preclinical studies, with bladder volumes 362 ranging from 250 ml to larger than human bladders. Thus preclinical studies require unique 363 heating technology that can localize heat within the desired bladder target which may be buried 364 over 3 to 12 mm from the skin surface. Hyperthermia studies are often performed in mice using 365 simple thermal conduction heating via waterbath, but that approach generally produces regional 366 if not systemic temperature rise that would complicate interpretation of biologic response to 367 specific bladder therapy. In recent years, a number of approaches have been reported for 368 improved localization of heat in animal bladders. 369 370
Radiative external microwave antenna heating 371
In order to elevate temperature in a urine filled bladder at depths of 3-8 mm below the skin of 372 
Correlation of Heating Technologies with Clinical Requirements 405
General characteristics of the clinical problem 406
As explained earlier, there are primarily two types of disease to be addressed in this review: 407 NMIBC and MIBC. These two diseases are quite different biologically and anatomically, and 408 require significantly different treatment approaches. The corresponding requirements for heating 409 these two diseases are also quite different. Superficial bladder cancers involve only the mucosa 410 and sub-mucosa layers along the inner bladder surface, generally with a thickness <2 mm. On 411 the other hand, MIBC by definition extends into the muscle layers of the bladder wall and even 412 into extravesical structures outside the bladder; this deeper disease presents a wide range of 413 technical challenges to effective heating. Thus optimal heating of NMIBC requires 414 homogeneous heating of the bladder interior extending < 2-3 mm into the bladder wall, and 415 ideally there would be minimal heating of normal tissues outside the bladder. Optimal treatment 416 of MIBC requires heating not only the bladder wall but also a variable amount of tissue outside 417 the bladder. Of all the available heating technology, some systems are better suited to limiting 418 the extent of heating to just a thin rim of target disease on the interior of the bladder, and other 419 devices are better suited to heating large regions of pelvis including bladder and surrounding 420
tissues. 421
Criteria for determining effectiveness of treatment include: 422
Homogeneity of heating around the interior surface of bladder 423
Depth of penetration of heating through bladder tissue 424
Circulation/mixing of drug in contact with inner surface of bladder wall 425
Heating of normal tissue outside the bladder 426
Heating of tumor tissue outside the bladder 427
Ease of heating 428
Patient tolerance 429 430
Clinical infrastructure requirements 431
In addition to comparing technological performance of the above mentioned systems by 432 characterizing their ability to localize and uniformly heat tumor, other important considerations 433 for selecting a hyperthermia system include the initial capital investment, space, supplies, and 434 personnel and time required to prepare for and apply each treatment. 435
436
Of the intravesical systems, the circulating fluid thermal conduction method is the most 437 straightforward to apply. Due to the known maximum temperature of the circulating fluid, this 438 approach has the lowest risk of side effects from uncontrolled excessive temperature. It also is 439 the least demanding of resources for calibration and quality assurance validation. The 440 intravesical microwave antenna system is similarly compact, but includes a power generator 441 that produces non-uniform power deposition around the antenna and unknown temperature 442 peaks in tissue. Thus this technology requires stepwise more quality assurance and personnel 443
training to obtain safe and reproducible performance. In either case, the intravesical systems 444 should be applied only for heating superficial NMIBC. 
Pros and Cons of Bladder Heating Technologies 466
A summary of advantages and disadvantages is provided in Table 2 for each of the heating 467 technologies described above. For treatment of NMIBC limited to the interior of bladder, 468 intravesical heating approaches appear most appropriate. As illustrated before, the simplest 469 way to heat bladder wall tumors is via the circulating, heated fluid approach. This has the 470 advantage of knowing both the maximum temperature anywhere in tissue and effective extent of 471 heating is limited to about 2-3 mm maximum penetration through the bladder wall, which is 472 sufficient for NMIBC. Thus, circulating fluid thermal conduction heating may be expected to 473 produce fewer toxicities compared to more complicated microwave heating approach that is 474 known to produce non-homogeneous power deposition with "hot spots" and potentially burns in 475 the posterior bladder wall and "cold spots" or places of ineffective heating at the dome and near 476 the trigone. Potential advantages of the intravesical microwave thermo-chemotherapy approach 477 stem from the increased penetration of microwave energy into somewhat thicker tumors (3-6 478 mm) and the use of circulating cooled drug to limit indiscriminant heating particularly in the 479 bladder neck and urethra. This claim may be overstated however, as the precooled drug 480 
